Our work demonstrated that fNDs were capable of enhancing drug accumulation and retention time in tumor cells, leading to continued tumor cell killing effect after clearance of drug treatment.
If acidic pH caused by cell growth is detrimental to continued cell growth, then continued supply of buffered medium might alleviate this problem.
Although, the identification of cancer associated antigens for targeted therapies has progressed, any successful treatment will need to overcome the barriers presented by MHC I downregulation, and coreceptor signaling between tumor cells, T cells and APCs leading to continued immune evasion.
It is well accepted that VEGF produced by tumor cells acts on neighboring VEGFR-expressing endothelial cells to promote angiogenesis for continued tumor growth.
These authors proposed that cross-reactivity between an OspA epitope and hLFA1, allows OspA primed T cells to remain activated by continued stimulation through cells expressing hLFA1, even after elimination of the spirochetes by antibiotic therapy, initiating an autoimmune response to hLFA1 in the joint [ 5, 6].
Where TCF is already active, neural stem and progenitor cells proliferate in response to continued TCF stimulation.
GIST cells resistant to imatinib demonstrated increased activation of the AKT pathway leading to continued cell growth and survival [ 32, 33].
In addition, the dislocation microstructure was found to evolve in a sequence of veins, walls-channels and elongated cells to attain an equiaxed cell arrangement with continued fatigue cycling.
After epigenetic silencing of p16INK4A, HMECs proliferate for an additional 30 50 population doublings before encountering a telomere-based barrier to continued cell division.
Further studies of ASS1 and arginine deprivation in normal immune cells are indicated, in addition to continued monitoring of patients for infection (see below) and modulation of tumour immunosurveillance in ongoing clinical trials of arginine-lowering agents.
